Related Experiment Video
Updated: Jul 29, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Special considerations concerning regulatory requirements and drug development for peptides and biotech products in
1F. Hoffmann-La Roche AG, Basel, Switzerland. andrea.braun@roche.com
Abstract:
The marketing authorization for a new medicinal product is based on the scientific assessment of its quality, safety and efficacy. The marketing authorization application (MAA) which covers all the relevant documentation can be filed in the EU via different application procedures. For peptides and biological products special issues have to be taken into consideration during drug development. Due to special production procedures and the complexity of the active substance itself, peptides and biotech products are subject to specific regulatory requirements. This leads to the necessity to discuss the development program of a new peptide or biotech product with the health authorities on a case by case basis. This article will focus on the special regulatory requirements for peptides and biotech products including the registration procedures as well as technical, preclinical and clinical issues.
Related Concept Videos
Drug Regulation
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
FDA Approved Drugs: Changes to Approved Drugs

